Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma
Open accessThe DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Immune checkpoint blockade is revolutionizing therapy for advanced cancer, but many patients do not respond to treatment. The identification of robust biomarkers that predict clinical response to specific checkpoint inhibitors is critical in order to stratify patients and to rationally select combinations in the context of an expanding array of therapeutic options. METHODS: We performed multiparameter flow cytometry on freshly isolated metastatic melanoma samples from 2 cohorts of 20 patients each prior to treatment and correlated the subsequent clinical response with the tumor immune phenotype. RESULTS: Increasing fractions of programmed cell death 1 high/cytotoxic T lymphocyte-associated protein 4 high (PD-1hiCTLA-4hi) cells within the tumor-infiltrating CD8+ T cell subset strongly correlated with response to therapy (RR) and progression-free survival (PFS). Functional analysis of these cells revealed a partially exhausted T cell phenotype. Assessment of metastatic lesions during anti-PD-1 therapy demonstrated a release of T cell exhaustion, as measured by an accumulation of highly activated CD8+ T cells within tumors, with no effect on Tregs. CONCLUSIONS: Our data suggest that the relative abundance of partially exhausted tumor-infiltrating CD8+ T cells predicts response to anti-PD-1 therapy. This information can be used to appropriately select patients with a high likelihood of achieving a clinical response to PD-1 pathway inhibition. FUNDING: This work was funded by a generous gift provided by Inga-Lill and David Amoroso as well as a generous gift provided by Stephen Juelsgaard and Lori Cook.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the presence of CD8 + PD-1 hi T cells in the tumors of patients with melanoma and patients with NSCLC prior to anti-PD-1 administration was predictive of treatment response and correlated with overall survival (146, 147).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [146]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Self-citationPredictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Self-citationBrahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,961
PD-L1 expression as a predictive biomarker in cancer immunotherapy
Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0983 · Cited by 2,291
Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766
Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70054-9 · Cited by 1,415
Cited by
Determining cell type abundance and expression from bulk tissues with digital cytometry
Newman, A. M., Steen, C. B., Liu, C. L., Gentles, A. J., Chaudhuri, A. A., Scherer, F., Khodadoust, M. S., Esfahani, M. S., Luca, B. A., Steiner, D., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0114-2 · Cited by 4,478
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
Bagchi, S., Yuan, R., & Engleman, E. G. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042020-042741 · Cited by 2,189
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.038 · Cited by 2,053
Immune checkpoint inhibitors: recent progress and potential biomarkers
Darvin, P., Toor, S. M., Sasidharan Nair, V., & Elkord, E. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0191-1 · Cited by 2,035
CD8+ T cell states in human cancer: insights from single-cell analysis
van der Leun, A. M., Thommen, D. S., & Schumacher, T. N. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0235-4 · Cited by 1,472
Mechanisms of resistance to immune checkpoint inhibitors
Jenkins, R. W., Barbie, D. A., & Flaherty, K. T. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.434 · Cited by 1,383
“For example, partially exhausted PD1þ CTLA-4þ CD8þ infiltrating T cells have been correlated with PD-1 response (Daud et al, 2016).”
BackgroundDistinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302
Hargadon, K. M., Johnson, C. E., & Williams, C. J. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.06.001 · Cited by 1,211
Beltra, J.-C., Manne, S., Abdel-Hakeem, M. S., Kurachi, M., Giles, J. R., Chen, Z., Casella, V., Ngiow, S. F., Khan, O., Huang, Y. J., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.014 · Cited by 1,082
IL-10 Family Cytokines IL-10 and IL-22: from Basic Science to Clinical Translation
Ouyang, W., & O’Garra, A. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.020 · Cited by 1,072
Clinical implications of T cell exhaustion for cancer immunotherapy
Chow, A., Perica, K., Klebanoff, C. A., & Wolchok, J. D. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00689-z · Cited by 1,044
Sun, L., Su, Y., Jiao, A., Wang, X., & Zhang, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01471-y · Cited by 1,014
Monitoring immune-checkpoint blockade: response evaluation and biomarker development
Nishino, M., Ramaiya, N. H., Hatabu, H., & Hodi, F. S. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.88 · Cited by 1,023
An Immune Atlas of Clear Cell Renal Cell Carcinoma
Chevrier, S., Levine, J. H., Zanotelli, V. R. T., Silina, K., Schulz, D., Bacac, M., Ries, C. H., Ailles, L., Jewett, M. A. S., Moch, H., et al. (2017) · Cell · doi:10.1016/j.cell.2017.04.016 · Cited by 1,004
Kamphorst, A. O., Pillai, R. N., Yang, S., Nasti, T. H., Akondy, R. S., Wieland, A., Sica, G. L., Yu, K., Koenig, L., Patel, N. T., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705327114 · Cited by 854
“CTLA-4 is expressed by PD-1 tumor infiltrating lymphocytes (TILs), and higher frequency of CTLA-4+ CD8 TILs has been recently associated with response to PD-1–targeted therapy in melanoma patients (19).”
BackgroundA Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer
Wagner, J., Rapsomaniki, M. A., Chevrier, S., Anzeneder, T., Langwieder, C., Dykgers, A., Rees, M., Ramaswamy, A., Muenst, S., Soysal, S. D., et al. (2019) · Cell · doi:10.1016/j.cell.2019.03.005 · Cited by 790
Kumagai, S., Togashi, Y., Kamada, T., Sugiyama, E., Nishinakamura, H., Takeuchi, Y., Vitaly, K., Itahashi, K., Maeda, Y., Matsui, S., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0769-3 · Cited by 783
Li, J., Byrne, K. T., Yan, F., Yamazoe, T., Chen, Z., Baslan, T., Richman, L. P., Lin, J. H., Sun, Y. H., Rech, A. J., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.06.006 · Cited by 750
Ringel, M. D., Sosa, J. A., Baloch, Z., Bischoff, L., Bloom, G., Brent, G. A., Brock, P. L., Chou, R., Flavell, R. R., Goldner, W., et al. (2025) · Thyroid® · doi:10.1177/10507256251363120 · Cited by 710
High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
Krieg, C., Nowicka, M., Guglietta, S., Schindler, S., Hartmann, F. J., Weber, L. M., Dummer, R., Robinson, M. D., Levesque, M. P., & Becher, B. (2018) · Nature Medicine · doi:10.1038/nm.4466 · Cited by 735
A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma
Huang, A. C., Orlowski, R. J., Xu, X., Mick, R., George, S. M., Yan, P. K., Manne, S., Kraya, A. A., Wubbenhorst, B., Dorfman, L., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0357-y · Cited by 686
Multidimensional communication in the microenvirons of glioblastoma
Broekman, M. L., Maas, S. L. N., Abels, E. R., Mempel, T. R., Krichevsky, A. M., & Breakefield, X. O. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0025-8 · Cited by 579
The foundations of immune checkpoint blockade and the ipilimumab approval decennial
Korman, A. J., Garrett-Thomson, S. C., & Lonberg, N. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00345-8 · Cited by 548
Enabling Technologies for Personalized and Precision Medicine
Ho, D., Quake, S. R., McCabe, E. R. B., Chng, W. J., Chow, E. K., Ding, X., Gelb, B. D., Ginsburg, G. S., Hassenstab, J., Ho, C.-M., et al. (2020) · Trends in Biotechnology · doi:10.1016/j.tibtech.2019.12.021 · Cited by 517
Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC
Camidge, D. R., Doebele, R. C., & Kerr, K. M. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0173-9 · Cited by 511
Lauss, M., Donia, M., Harbst, K., Andersen, R., Mitra, S., Rosengren, F., Salim, M., Vallon-Christersson, J., Törngren, T., Kvist, A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01460-0 · Cited by 470
Beyond immune checkpoint blockade: emerging immunological strategies
Kubli, S. P., Berger, T., Araujo, D. V., Siu, L. L., & Mak, T. W. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00155-y · Cited by 461
CD8+ T cells in the cancer-immunity cycle
Giles, J. R., Globig, A.-M., Kaech, S. M., & Wherry, E. J. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.005 · Cited by 449
PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer
Oh, S. A., Wu, D.-C., Cheung, J., Navarro, A., Xiong, H., Cubas, R., Totpal, K., Chiu, H., Wu, Y., Comps-Agrar, L., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0075-x · Cited by 459
Prat, A., Navarro, A., Paré, L., Reguart, N., Galván, P., Pascual, T., Martínez, A., Nuciforo, P., Comerma, L., Alos, L., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3556 · Cited by 455
“porting this hypothesis is a recent study using flow cytometry on freshly isolated metastatic melanoma samples from two cohorts of 20 patients, revealing that increasing fractions of PD1-high/ CTL–associated protein four high (PD1hiCTLA-4hi) cells within the tumor-infiltrating CD8þ T-cell subset strongly correlates wi…”
(2016) · Oncotarget · doi:10.18632/oncotarget · Cited by 386
TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
Bertrand, F., Montfort, A., Marcheteau, E., Imbert, C., Gilhodes, J., Filleron, T., Rochaix, P., Andrieu-Abadie, N., Levade, T., Meyer, N., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02358-7 · Cited by 384
“In fi ltration of human melanoma tumors by CD8+ T cells, which co-express PD-1 and CTLA-4 at high levels and produce IFN-γ ef fi ciently but not TNF, has been proposed as a good predictive marker of anti-PD-1 therapy 35 .”
Wang, Y., Deng, W., Li, N., Neri, S., Sharma, A., Jiang, W., & Lin, S. H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00185 · Cited by 374
Kugel, C. H., Douglass, S. M., Webster, M. R., Kaur, A., Liu, Q., Yin, X., Weiss, S. A., Darvishian, F., Al-Rohil, R. N., Ndoye, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1116 · Cited by 367
Li, F., Li, C., Cai, X., Xie, Z., Zhou, L., Cheng, B., Zhong, R., Xiong, S., Li, J., Chen, Z., et al. (2021) · eClinicalMedicine · doi:10.1016/j.eclinm.2021.101134 · Cited by 363
Biomarkers of response to PD-1/PD-L1 inhibition
Maleki Vareki, S., Garrigós, C., & Duran, I. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.06.001 · Cited by 318
Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma
Maibach, F., Sadozai, H., Seyed Jafari, S. M., Hunger, R. E., & Schenk, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02105 · Cited by 312
Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis
Lee, J. C., Mehdizadeh, S., Smith, J., Young, A., Mufazalov, I. A., Mowery, C. T., Daud, A., & Bluestone, J. A. (2020) · Science Immunology · doi:10.1126/sciimmunol.aba0759 · Cited by 308
Self-citationImmune infiltration in renal cell carcinoma
Zhang, S., Zhang, E., Long, J., Hu, Z., Peng, J., Liu, L., Tang, F., Li, L., Ouyang, Y., & Zeng, Z. (2019) · Cancer Science · doi:10.1111/cas.13996 · Cited by 305
PD-1 and PD-L1 antibodies in cancer: current status and future directions
Balar, A. V., & Weber, J. S. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-1954-6 · Cited by 298
Haist, M., Stege, H., Grabbe, S., & Bros, M. (2021) · Cancers · doi:10.3390/cancers13020210 · Cited by 295
“, the frequency, composition, and activation status [9,10] of tumor-infiltrating lymphocytes (TIL), are predictive for the responsiveness toward ICI treatment.”
BackgroundPD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
Xu-Monette, Z. Y., Zhang, M., Li, J., & Young, K. H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01597 · Cited by 288
Taube, J. M., Akturk, G., Angelo, M., Engle, E. L., Gnjatic, S., Greenbaum, S., Greenwald, N. F., Hedvat, C. V., Hollmann, T. J., Juco, J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000155 · Cited by 283
Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities
Pauken, K. E., Dougan, M., Rose, N. R., Lichtman, A. H., & Sharpe, A. H. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.04.002 · Cited by 280
Frameshift events predict anti–PD-1/L1 response in head and neck cancer
Hanna, G. J., Lizotte, P., Cavanaugh, M., Kuo, F. C., Shivdasani, P., Frieden, A., Chau, N. G., Schoenfeld, J. D., Lorch, J. H., Uppaluri, R., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.98811 · Cited by 275
PD1 signal transduction pathways in T cells
Arasanz, H., Gato-Cañas, M., Zuazo, M., Ibañez-Vea, M., Breckpot, K., Kochan, G., & Escors, D. (2017) · Oncotarget · doi:10.18632/oncotarget.17232 · Cited by 270
Oliva, M., Spreafico, A., Taberna, M., Alemany, L., Coburn, B., Mesia, R., & Siu, L. L. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy507 · Cited by 260
Correlation of immune phenotype with IDH mutation in diffuse glioma
Berghoff, A. S., Kiesel, B., Widhalm, G., Wilhelm, D., Rajky, O., Kurscheid, S., Kresl, P., Wöhrer, A., Marosi, C., Hegi, M. E., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox054 · Cited by 254
Naing, A., Infante, J. R., Papadopoulos, K. P., Chan, I. H., Shen, C., Ratti, N. P., Rojo, B., Autio, K. A., Wong, D. J., Patel, M. R., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.10.007 · Cited by 251
Amaro, A., Gangemi, R., Piaggio, F., Angelini, G., Barisione, G., Ferrini, S., & Pfeffer, U. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9663-3 · Cited by 241
(2019) · doi:10.1158/2159-8290.cd-18-1495 · Cited by 231
Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine?
Steuer, C. E., & Ramalingam, S. S. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.8770 · Cited by 228
Diab, A., Tannir, N. M., Bentebibel, S.-E., Hwu, P., Papadimitrakopoulou, V., Haymaker, C., Kluger, H. M., Gettinger, S. N., Sznol, M., Tykodi, S. S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1510 · Cited by 237
Caswell, D. R., & Swanton, C. (2017) · BMC Medicine · doi:10.1186/s12916-017-0900-y · Cited by 218
Buder-Bakhaya, K., & Hassel, J. C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01474 · Cited by 217
Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities
Rabbie, R., Ferguson, P., Molina‐Aguilar, C., Adams, D. J., & Robles‐Espinoza, C. D. (2019) · The Journal of Pathology · doi:10.1002/path.5213 · Cited by 217
Dosset, M., Vargas, T. R., Lagrange, A., Boidot, R., Végran, F., Roussey, A., Chalmin, F., Dondaine, L., Paul, C., Marie-Joseph, E. L., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1433981 · Cited by 210
Kim, K. H., Cho, J., Ku, B. M., Koh, J., Sun, J.-M., Lee, S.-H., Ahn, J. S., Cheon, J., Min, Y. J., Park, S.-H., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1449 · Cited by 205
Y chromosome loss in cancer drives growth by evasion of adaptive immunity
Abdel-Hafiz, H. A., Schafer, J. M., Chen, X., Xiao, T., Gauntner, T. D., Li, Z., & Theodorescu, D. (2023) · Nature · doi:10.1038/s41586-023-06234-x · Cited by 197
Zuazo, M., Arasanz, H., Fernández‐Hinojal, G., García‐Granda, M. J., Gato, M., Bocanegra, A., Martínez, M., Hernández, B., Teijeira, L., Morilla, I., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201910293 · Cited by 198
Immunoregulatory functions of VISTA
Nowak, E. C., Lines, J. L., Varn, F. S., Deng, J., Sarde, A., Mabaera, R., Kuta, A., Le Mercier, I., Cheng, C., & Noelle, R. J. (2017) · Immunological Reviews · doi:10.1111/imr.12525 · Cited by 197
Gettinger, S. N., Choi, J., Mani, N., Sanmamed, M. F., Datar, I., Sowell, R., Du, V. Y., Kaftan, E., Goldberg, S., Dong, W., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05032-8 · Cited by 191
Duraiswamy, J., Turrini, R., Minasyan, A., Barras, D., Crespo, I., Grimm, A. J., Casado, J., Genolet, R., Benedetti, F., Wicky, A., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.10.008 · Cited by 190
HDAC inhibition potentiates immunotherapy in triple negative breast cancer
Terranova-Barberio, M., Thomas, S., Ali, N., Pawlowska, N., Park, J., Krings, G., Rosenblum, M. D., Budillon, A., & Munster, P. N. (2017) · Oncotarget · doi:10.18632/oncotarget.23169 · Cited by 182
Self-citationChen, H., Chong, W., Wu, Q., Yao, Y., Mao, M., & Wang, X. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01113 · Cited by 180
Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer
Terranova-Barberio, M., Pawlowska, N., Dhawan, M., Moasser, M., Chien, A. J., Melisko, M. E., Rugo, H., Rahimi, R., Deal, T., Daud, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17414-y · Cited by 177
Self-citationDodagatta-Marri, E., Meyer, D. S., Reeves, M. Q., Paniagua, R., To, M. D., Binnewies, M., Broz, M. L., Mori, H., Wu, D., Adoumie, M., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0493-9 · Cited by 177
“4d, Additional file 3: Figure S4), that have also been associated with active anti-tumor responses in human tumors [34].”
BackgroundSelf-citationTargeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8+ T Cell Apoptosis
Qiao, J., Liu, Z., Dong, C., Luan, Y., Zhang, A., Moore, C., Fu, K., Peng, J., Wang, Y., Ren, Z., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.005 · Cited by 176
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Diggs, L. P., & Hsueh, E. C. (2017) · Biomarker Research · doi:10.1186/s40364-017-0093-8 · Cited by 173
Johnson, D. B., Bordeaux, J., Kim, J. Y., Vaupel, C., Rimm, D. L., Ho, T. H., Joseph, R. W., Daud, A. I., Conry, R. M., Gaughan, E. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0309 · Cited by 171
Self-citationde Groot, J., Penas-Prado, M., Alfaro-Munoz, K., Hunter, K., Pei, B. L., O’Brien, B., Weathers, S.-P., Loghin, M., Kamiya Matsouka, C., Yung, W. K. A., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noz185 · Cited by 170
Ali, N., & Rosenblum, M. D. (2017) · Immunology · doi:10.1111/imm.12791 · Cited by 167
Self-citationHorton, B. L., Williams, J. B., Cabanov, A., Spranger, S., & Gajewski, T. F. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0249 · Cited by 168
Low-Dose IFNγ Induces Tumor Cell Stemness in Tumor Microenvironment of Non–Small Cell Lung Cancer
Song, M., Ping, Y., Zhang, K., Yang, L., Li, F., Zhang, C., Cheng, S., Yue, D., Maimela, N. R., Qu, J., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0596 · Cited by 163
Intratumoral Immunotherapy—Update 2019
Hamid, O., Ismail, R., & Puzanov, I. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0438 · Cited by 161
Perplexing Role of P-Glycoprotein in Tumor Microenvironment
Robinson, K., & Tiriveedhi, V. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00265 · Cited by 176
Zhu, J., Armstrong, A. J., Friedlander, T. W., Kim, W. K., Pal, S. K., George, D. J., & Zhang, T. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0314-1 · Cited by 166
Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma
Algazi, A. P., Twitty, C. G., Tsai, K. K., Le, M., Pierce, R., Browning, E., Hermiz, R., Canton, D. A., Bannavong, D., Oglesby, A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2217 · Cited by 147
Self-citationThe role of immune checkpoint inhibition in the treatment of ovarian cancer
Gaillard, S. L., Secord, A. A., & Monk, B. J. (2016) · Gynecologic Oncology Research and Practice · doi:10.1186/s40661-016-0033-6 · Cited by 165
Development and validation of an immune‐related prognostic signature in lung adenocarcinoma
Sun, S., Guo, W., Wang, Z., Wang, X., Zhang, G., Zhang, H., Li, R., Gao, Y., Qiu, B., Tan, F., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3240 · Cited by 161
Wang, C., Sandhu, J. S., Ouyang, C., Ye, J., Lee, P. P., & Fakih, M. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.18416 · Cited by 144
Toward Biomaterials for Enhancing Immune Checkpoint Blockade Therapy
Fan, Q., Chen, Z., Wang, C., & Liu, Z. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201802540 · Cited by 129
Nosrati, A., Tsai, K. K., Goldinger, S. M., Tumeh, P., Grimes, B., Loo, K., Algazi, A. P., Nguyen-Kim, T. D. L., Levesque, M., Dummer, R., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.70 · Cited by 127
Self-citation89Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer
England, C. G., Jiang, D., Ehlerding, E. B., Rekoske, B. T., Ellison, P. A., Hernandez, R. T., Barnhart, T. E., McNeel, D. G., Huang, P., & Cai, W. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3803-4 · Cited by 126
Role of immune-checkpoint inhibitors in lung cancer
Jain, P., Jain, C., & Velcheti, V. (2018) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465817750075 · Cited by 139
Zhou, Y., Lee, J. J., & Yuan, Y. (2019) · Statistics in Medicine · doi:10.1002/sim.8361 · Cited by 122
Jílková, Z. M., Aspord, C., & Decaens, T. (2019) · Cancers · doi:10.3390/cancers11101554 · Cited by 123
In vivo labeling reveals continuous trafficking of TCF-1+ T cells between tumor and lymphoid tissue
Li, Z., Tuong, Z. K., Dean, I., Willis, C., Gaspal, F., Fiancette, R., Idris, S., Kennedy, B. C., Ferdinand, J. R., Peñalver, A., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20210749 · Cited by 124
The role of biomarkers in personalized immunotherapy
Sankar, K., Ye, J. C., Li, Z., Zheng, L., Song, W., & Hu-Lieskovan, S. (2022) · Biomarker Research · doi:10.1186/s40364-022-00378-0 · Cited by 111
Qi, Z., Xu, Z., Zhang, L., Zou, Y., Li, J., Yan, W., Li, C., Liu, N., & Wu, H. (2022) · Nature Communications · doi:10.1038/s41467-021-27833-0 · Cited by 137
Combinatorial immunotherapy and nanoparticle mediated hyperthermia
Moy, A. J., & Tunnell, J. W. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.008 · Cited by 120
Immunotherapy for Chronic Hepatitis B Virus Infection
Bertoletti, A., & Bert, N. L. (2018) · Gut and Liver · doi:10.5009/gnl17233 · Cited by 110
Broos, K., Lecocq, Q., Raes, G., Devoogdt, N., Keyaerts, M., & Breckpot, K. (2018) · Theranostics · doi:10.7150/thno.24762 · Cited by 112
Advances in Proteomic Techniques for Cytokine Analysis: Focus on Melanoma Research
Skalníková, H. K., Čížková, J., Červenka, J., & Vodička, P. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122697 · Cited by 116
Prognostic value of B cells in cutaneous melanoma
Selitsky, S. R., Mose, L. E., Smith, C. C., Chai, S., Hoadley, K. A., Dittmer, D. P., Moschos, S. J., Parker, J. S., & Vincent, B. G. (2019) · Genome Medicine · doi:10.1186/s13073-019-0647-5 · Cited by 120
Cutaneous melanoma and the immunotherapy revolution (Review)
Leonardi, G. C., Candido, S., Falzone, L., Spandidos, D. A., & Libra, M. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5088 · Cited by 123
Kim, H., Park, S., Jeong, S., Lee, Y. J., Lee, H., Kim, C. G., Kim, K. H., Hong, S., Lee, J., Kim, S., et al. (2019) · Hepatology · doi:10.1002/hep.30881 · Cited by 114
Maity, A. M., Mick, R., Huang, A. C. C., George, S. M., Farwell, M. D., Lukens, J. N., Berman, A. T., Mitchell, T. C., Bauml, J., Schuchter, L. M., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0281-9 · Cited by 110
Biton, J., Ouakrim, H., Dechartres, A., Alifano, M., Mansuet‐Lupo, A., Si, H., Halpin, R., Creasy, T. H., Bantsimba-Malanda, C., Arrondeau, J., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201706-1110oc · Cited by 118
Metadata
- Authors
- Daud, A. I., Loo, K., Pauli, M. L., Sanchez-Rodriguez, R., Sandoval, P. M., Taravati, K., Tsai, K., Nosrati, A., Nardo, L., Alvarado, M. D., Algazi, A. P., Pampaloni, M. H., Lobach, I. V., Hwang, J., Pierce, R. H., Gratz, I. K., Krummel, M. F., & Rosenblum, M. D.
- Affiliations
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
- University of California, San Francisco (US)
- University of Salzburg (AT)
- Corresponding author
- Rosenblum, Michael D.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2016-08-15
- Volume
- 126
- Issue
- 9
- Pages
- 3447-3452
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC5004965
- OpenAlex
- W2512255557
- Cited by
- 525
- References
- 23
- Citations by year
- 2026: 17 · 2025: 28 · 2024: 37 · 2023: 47 · 2022: 51 · 2021: 55 · 2020: 89 · 2019: 61 · 2018: 71 · 2017: 64 · 2016: 5
- FWCI
- 36.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- International Business Machines Corporation
- National Institutes of Health (1dp2ar068130-01)
- University of California, San Francisco
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (DP2-AR068130, R21AR066821, K08AR062064)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- metastatic melanoma, anti-PD-1 therapy, immune checkpoint blockade, tumor immune profiling, CD8+ T cell exhaustion, tumor-infiltrating lymphocytes, predictive biomarkers, treatment response prediction, progression-free survival, regulatory T cells
- MeSH terms
- Biopsy, Female, Flow Cytometry, Humans, Immune System, Lymphocyte Activation, Male, Melanoma, Neoplasm Metastasis, Phenotype, Skin Neoplasms, Cohort Studies, T-Lymphocyte Subsets, Lymphocytes, Tumor-Infiltrating, Leukocyte Common Antigens, CD8-Positive T-Lymphocytes, Cell Line, Tumor, Tumor Microenvironment, CTLA-4 Antigen, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.